Incyte Corporation — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021; filed August 3, 2021. Incyte is a biopharmaceutical company developing and commercializing therapeutics. Commercial products include JAKAFI, ICLUSIG and PEMAZYRE; MONJUVI is co-commercialized with MorphoSys. The company reports one operating segment.
Financial performance and liquidity
Amounts below are in millions of U.S. dollars, except per-share data and percentages. Comparisons are with the same 2020 period.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Total revenue | $705.7 | $688.0 | $1,310.4 | $1,256.6 |
| Product revenue | $575.2 | $500.3 | $1,080.0 | $987.0 |
| Royalty revenue | $120.6 | $92.8 | $220.5 | $174.5 |
| Milestone and contract revenue | $10.0 | $95.0 | $10.0 | $95.0 |
| Operating income (loss) | $140.8 | $230.8 | $239.6 | $(433.2) |
| Net income (loss) | $149.5 | $290.3 | $203.0 | $(430.3) |
| Diluted EPS | $0.67 | $1.32 | $0.91 | $(1.98) |
| Operating margin, approximate | 20.0% | 33.5% | 18.3% | Not meaningful (operating loss) |
- Revenue drivers: Q2 product revenue rose 15%, including JAKAFI revenue of $529.1 million, ICLUSIG of $28.2 million and PEMAZYRE of $17.9 million. Royalties increased 30%, led by JAKAVI ($82.0 million) and OLUMIANT ($36.0 million).
- Costs: Q2 cost of product revenue was $38.0 million. Research and development was $343.5 million, up from $286.6 million, and selling, general and administrative expense was $168.9 million, up from $118.0 million. Six-month 2020 R&D included a $750 million MorphoSys upfront payment, contributing to the prior-period operating loss.
- Cash flow: Six-month operating cash flow was $379.0 million, compared with cash used of $414.0 million in 2020. Investing activities used $108.9 million, including $114.4 million of capital expenditures; financing activities provided $16.5 million. Cash, cash equivalents, restricted cash and investments increased $284.5 million to $1.799 billion.
- Liquidity and obligations: Cash, cash equivalents and marketable securities totaled approximately $2.081 billion at June 30. Total assets were $3.905 billion and stockholders’ equity was $2.936 billion. The balance sheet lists $34.2 million of finance lease liabilities and $259.0 million of acquisition-related contingent consideration; no conventional borrowing balance is presented. Management said available cash and operating cash flow should meet capital needs for the foreseeable future.
Material changes versus the prior comparable period
- Q2 revenue increased 2.6%, but net income fell 48.5%; operating margin also declined. Higher product and royalty revenue was partly offset by lower milestone revenue ($10 million versus $95 million), increased R&D and SG&A, and a smaller unrealized investment gain ($26.8 million versus $72.3 million).
- Six-month revenue increased 4.3%, while net income shifted to $203.0 million from a $430.3 million loss. The comparison is heavily affected by the $750 million MorphoSys upfront payment recorded in 2020. Six-month 2021 investment results included a $0.9 million unrealized loss, versus a $24.1 million gain in 2020.
- JAKAFI remained the largest revenue source. Management attributed Q2 growth to higher JAKAFI volume and price; it also cautioned that customer purchasing patterns, including inventory build-ahead of price increases, may cause quarterly variation.
- Cash and cash equivalents rose from $1.513 billion at year-end 2020 to $1.798 billion at June 30, 2021. Property and equipment increased to $661.4 million, principally amid construction activity.
Outlook, commentary, risks and unusual items
- No numerical revenue or earnings guidance is provided in the supplied filing text. Management expects existing cash resources and operating cash flow to fund capital needs for the foreseeable future.
- Major development and regulatory uncertainties include FDA review of ruxolitinib cream for atopic dermatitis, whose action date was extended to September 2021; FDA review of ruxolitinib for steroid-refractory chronic GVHD, also extended; and a July 2021 FDA complete response letter for retifanlimab in anal cancer. PEMAZYRE received approvals in Japan, Europe and Taiwan during the period; management reported positive Phase III topline vitiligo results and planned an sNDA.
- Incyte agreed to a $12.6 million DOJ settlement, plus statutory fees, concerning speaker and patient-assistance programs. The amount was recorded in SG&A during the six months. The company denied improper claims.
- Key business risks include reliance on JAKAFI and a concentrated group of product distributors, pricing and reimbursement pressure, competition and generic challenges, clinical and regulatory outcomes, dependence on collaborators and third-party manufacturers, and potential COVID-19 effects on demand, trials and supply chains.
- Other notable exposures include fair-value volatility in strategic equity investments and a Level 3 contingent consideration liability tied to future ICLUSIG royalties. The company also disclosed supplier concentration for some inventory components and a full valuation allowance against U.S. and Swiss net deferred tax assets.
Important facts for investors to verify
- Whether JAKAFI growth and rising partner royalties can offset the business’s continued dependence on JAKAFI and lower or variable milestone revenue.
- Regulatory decisions and commercial progress for ruxolitinib cream, chronic GVHD ruxolitinib, retifanlimab and other late-stage programs, including developments after the filing date.
- How much reported earnings reflect operating performance versus investment fair-value changes and one-time collaboration or legal items.
- Cash generation, planned capital expenditures and construction completion timing; the filing expected the Delaware headquarters building and Swiss production facility to become operational in the first half of 2022.
- The scale and timing of collaboration, royalty, contingent-consideration and other contractual payments, and any updates to the DOJ settlement obligations.